Scholars@Duke
Kyle C. Strickland

Kyle C. Strickland

Adjunct Associate Professor of Pathology
Pathology
kyle.strickland@duke.edu
Box 3712, Durham, NC 27710
40 Duke Medicine Circle, Purple Zone, Rm 3418, Durham, NC 27710

Scholarly Works - Conferences

Interaction between VEGF-A and immune checkpoint targets in triple-negative breast cancer and mechanisms of immune evasion and tumor progression.

Conference Journal of Clinical Oncology · June 1, 2024 1096Background: Immune checkpoint inhibitors (ICIs) have revolutionized the treatment triple negative breast cancer (TNBC). However, not all patients with TNBC benefit from the addition of ICIs due to factors such as intrinsic and acquired resistance to IC ... Full text Cite

Novel HLA-Ilo/HLA-IIhi phenotype and immune evasion in triple-negative breast cancer

Conference Journal of Clinical Oncology · January 1, 2024 Background: Immune checkpoint inhibitors (ICIs) are a therapeutic option for patients with triple-negative breast cancer (TNBC), however resistance and non-response remain an unmet clinical need. Human leukocyte antigens (HLAs) play an important role in in ... Full text Cite

A machine learning algorithm based on multi-omics biomarkers for the detection of tumor microsatellite instability

Conference Journal of Clinical Oncology · January 1, 2024 Background: Microsatellite instability (MSI) occurs via defects in mismatch repair (MMR) and is characterized by high tumor mutational burden (TMB) and a robust inflammatory response. Accurate MSI-high classification of immune-evasive tumors is vital due t ... Full text Cite

Genetic counseling referrals after next generation sequencing testing.

Conference JOURNAL OF CLINICAL ONCOLOGY · May 20, 2020 Link to item Cite

Abstract 2796: Development of a RAD51-based assay for determining homologous recombination proficiency and PARP inhibitor sensitivity

Conference Cancer Research · July 1, 2017 AbstractHomologous recombination (HR) repair deficiency confers sensitivity to inhibitors of poly(ADP-ribose) polymerase (PARP). To date, the identification of tumors with impaired HR has relied on genomic f ... Full text Cite